Japan Weighs Drug Cost Cut of around 400 Billion Yen in Off-Year Re-Pricing, Expanded Coverage Including Products with Smaller-than-Average Price Gap Too

The Japanese government is apparently leaning towards shedding drug spending by around 400 billion yen in “off-year” re-pricing next April, as it is likely to set a threshold that would cover not only products with NHI-market price gaps larger than...read more